Deruxtecan

Overview

Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing Trastuzumab deruxtecan ( HY-138298A ) and Patritumab deruxtecan ( HY-P99813 ).

Application

Products | Products > Disease Areas > Luminal Breast Cancer | Products > Disease Areas > HER-2 Positive Breast Cancer | Products > Disease Areas > Triple-Negative Breast Cancer | Products > Disease Areas > Metastatic Breast Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Signaling Pathways > Antibody-Drug Conjugate/ADC Related | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > Drug-Linker Conjugates for ADC

Product Information

• Catalog No.: HY-13631E
• CAS No.: 1599440-13-7
• Molecular Formula: C52H56FN9O13
• Molecular Weight: 1034.05
• Purity: 99.84%
• Storage: -20°C, protect from light, stored under nitrogen * The compound is unstable in solutions, freshly prepared is recommended.
• Solubility: 1.75 mg/mL (1.69 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source